Close menu




February 8th, 2021 | 09:48 CET

Lang & Schwarz, Deutsche Rohstoff, NanoRepro - Top Picks: German Small Caps!

  • Investments
Photo credits: Deutsche Rohstoff AG

Many studies show that small listed companies, so-called small caps, generate higher returns over more extended periods than larger corporations. A broadly diversified small-cap portfolio, when combined with mid and large caps, increases returns and reduces risk in the overall context. Thus, small caps should not be a side issue when it comes to investing. We present three exciting and promising German small caps.

time to read: 4 minutes | Author: Carsten Mainitz
ISIN: DE000A0XYG76 , DE0006459324 , DE0006577109

Table of contents:


    LANG & SCHWARZ AG - Records continue to be set

    At the beginning of the year, Lang & Schwarz AG reported phenomenal figures for the fourth quarter and the past fiscal year, with the stock trading in the EUR 75 range. The core business of stock exchange trading continues to boom. In addition to on-exchange trading, the subsidiary Lang & Schwarz Tradecenter also offers off-exchange trading via its own platform LS-X, which has established itself as the No.3 in Germany.

    Last Monday, Lang & Schwarz published the results of its trading activities (net interest income plus net commission income and trading profit) for January. This number increased to EUR 20 million and was almost seven times higher than the previous year's figure. The record result is even more impressive when viewed in relation to other data. With the January result, the Company has exceeded the trading activity of the entire opening quarter of 2020 by almost 40%. And the Company has already brought in more than 70% of the record result of Q4 2020!

    No wonder, then, that the stock gained over 30% in the past week alone, reaching a new all-time high. At prices of around EUR 130, the Company is now valued at a good EUR 400 million. As long as the stock markets remain so sunny and carefree, investors in Lang & Schwarz shares will outperform the market. However, it is also clear that growth trends cannot continue exponentially into eternity. From a fundamental analytical perspective, the stock is not overvalued, even at the new all-time high, given the earnings achieved in 2020 and the outlook, which makes another record year likely.

    DEUTSCHE ROHSTOFF AG - With new oil wells, the Company's cash register is ringing

    Deutsche Rohstoff is the only pure commodity share with German origins on the national stock market. The Mannheim-based Group identifies, develops and sells attractive raw material deposits in North America, Australia and Europe. For some time now, the focus has been on developing oil and gas deposits in the US. Acting opportunistically, the Company has proven good timing in the past when disposing of gold projects and US oil projects. Often underestimated are the mining projects and investments that the Group holds in its portfolio. In particular, investors should look at Almonty Industries, in which the Mannheim-based Company has a stake. Almonty is currently developing the largest tungsten mine outside China and has excellent chances to establish itself as one of the most important global producers of the strategic metal.

    Last Friday, Deutsche Rohstoff announced an update on US oil Company Cub Creek Energy with the immediate start of drilling (Knight well site, just west of the Olander well site). Plans call for up to 12 horizontal wells with 2.25 miles of horizontal length. The Corporation expects production to commence in the fourth quarter of the current year. The cost of the drilling program is estimated to be up to USD 60 million, of which Cub Creek will be responsible for approximately 90%. Financing will come from cash flow generated, a credit line provided, and corporate funds. There was also good news from the Olander drilling site. Since the beginning of January, production here has started up again in the wake of rising oil prices. By the end of January, production had already reached almost 4,000 BOE. The Group expects a further increase in February.

    While in the first phase of the Corona pandemic, it looked as if the world would no longer demand oil; the situation has eased again. Rising crude oil prices and tightening forward curves will gradually demonstrate to investors the value of Deutsche Rohstoff's oil projects. Forward-looking investors have already bought in or should do so soon.

    NANOREPRO AG - Is the share already too expensive or still too cheap?

    The third stock today is much more speculative than the two previous stocks. The share price already contains some advance praise. Also, the Company's history has shown that several potentials have not been realized. The volatility of the share should also not be underestimated. But at least for traders, these are always exciting conditions. Experts in chart technology even see a short-term chance of a price gain of more than 40%.

    Marburg-based NanoRepro AG develops, produces and sells medical self-tests and has been one of the innovation leaders in this growth market for years. The portfolio in self-diagnostics currently comprises 25 products, including pregnancy tests, colorectal cancer screening tests, various allergy tests and an HIV test.

    In early January, the Company announced that it had submitted a Corona antigen test for home use to the relevant authorities. This test is saliva-based and gives a result after about 15 to 20 minutes. However, the Company did not say when an approval decision could be expected. If the Marburg-based Company succeeds in launching the Corona test for end consumers, the share will face a revaluation. In the event of a failure, the share price could suffer significant losses.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Juliane Zielonka on December 1st, 2022 | 10:44 CET

    Aspermont, Twitter, Apple - Strong numbers, strong visions and marketplace power

    • Digitization
    • Commodities
    • Investments

    The Australian media company for the commodities industry has presented its latest figures. The results are impressive, with total revenue up 17% YOY, among other things. This industry pioneer illustrates just how valuable access to high-quality information can be. Perhaps soon to disappear from the scene is Elon Musk's Twitter: Find out how strong its dependence on the App Store giant is and what impact Apple fees may have on its revenue model here.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Stefan Feulner on November 29th, 2022 | 13:32 CET

    Nvidia, Meta Materials, SFC Energy - Strong signs

    • Technology
    • Investments
    • nanotechnology

    After turbulent months on the technology stock markets with high markdowns, a bottoming out is taking place across the board. While many companies are reporting better-than-expected figures, investors are also buying oversold companies whose quarterly figures were below analysts' consensus. Due to the still high fluctuation range, high trading profits can be expected.

    Read